Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-26 @ 1:17 PM
Ignite Modification Date:
2025-12-26 @ 1:17 PM
NCT ID:
NCT01053806
Brief Summary:
To evaluate the overall response rate of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients (INT-2 and High risk defined by IPSS), and patients with low and int-1 who are considered to be at high risk due to unfavorable additional factors.
* To evaluate the safety of the combination of 5-azacitidine + Lenalidomide in high risk MDS patients.
* To evaluate the hematological improvement rate.
* To evaluate the cytogenetic response rate.
* To evaluate the Progression free survival (PFS).
* To assess Quality of life.
Study:
NCT01053806
Study Brief:
Protocol Section:
NCT01053806